Tech Company Financing Transactions
N-Zyme Biomedical Funding Round
N-Zyme Biomedical, operating out of Wauwatosa, scored $4.6 million in investment from private investors.
Transaction Overview
Company Name
Announced On
7/22/2026
Transaction Type
Venture Equity
Amount
$4,600,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the advancement of its Phase 2 clinical programs and further the development of its new pepsin inhibitor platform for reflux disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1225 Discovery Parkway 260E
Wauwatosa, WI 53226
USA
Wauwatosa, WI 53226
USA
Phone
Undisclosed
Website
Email Address
Overview
N-Zyme intends to improve the quality of life for millions of people around the globe by developing the first safe, effective and efficient treatments for Laryngopharyngeal Reflux (LPR). N-Zyme Biomedical seeks to provide much-needed treatments for the millions of people in the US and worldwide that suffer from LPR.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Franco Vigile
Chief Scientific Officer
Nikki Johnston
Browse more venture capital transactions:
Prev: 7/22/2026: Karoo Health venture capital transaction
Next: 7/22/2026: Palladyne AI venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs